Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 50

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 50
---
 are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those dates.

<div align='center'>S-i</div>

### ABOUT THIS PROSPECTUS
This prospectus is part of an automatic shelf registration statement on Form S-3ASR that we filed with the SEC as a “well-known seasoned issuer” as defined in Rule 405 under the Securities Act, using a “shelf” registration process. Under this shelf registration statement, we may from time to time sell any combination of the securities described in the base prospectus included in the shelf registration statement in one or more offerings. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $300,000,000 from time to time through Jefferies, acting as our sales agent. Under this prospectus, we may offer shares of our common stock having an aggregate offering price of up to $200,000,000 of the $300,000,000 authorized under the sales agreement from time to time at prices and on terms to be determined by market conditions at the time of offering. If we wish to offer and sell additional shares of our common stock under the sales agreement in excess of the $200,000,000 being registered under this prospectus, for up to an additional $100,000,000, we must file with the SEC one or more additional prospectus supplements to register under the Securities Act the offer and sale of any such additional shares of our common stock we wish to offer and sell from time to time under the sales agreement.

Before buying any of the shares of our common stock offered hereby, we urge you to read carefully this prospectus and all of the information incorporated by reference herein, as well as the additional information described below under the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference.” These documents contain important information that you should consider when making your investment decision. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus that was filed with the SEC before the date of this prospectus